Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by American Century Companies Inc.

American Century Companies Inc. boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 24.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,358 shares of the medical research company’s stock after buying an additional 267 shares during the period. American Century Companies Inc.’s holdings in Charles River Laboratories International were worth $502,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in CRL. Fred Alger Management LLC acquired a new position in shares of Charles River Laboratories International in the first quarter valued at approximately $26,000. Centerpoint Advisors LLC increased its holdings in shares of Charles River Laboratories International by 60.0% in the second quarter. Centerpoint Advisors LLC now owns 80 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 30 shares during the period. Berman Capital Advisors LLC increased its holdings in shares of Charles River Laboratories International by 28.5% in the first quarter. Berman Capital Advisors LLC now owns 185 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 41 shares during the period. Huntington National Bank increased its holdings in shares of Charles River Laboratories International by 45.1% in the second quarter. Huntington National Bank now owns 177 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 55 shares during the period. Finally, Eaton Vance Management acquired a new position in shares of Charles River Laboratories International in the first quarter valued at approximately $73,000. 93.28% of the stock is currently owned by institutional investors and hedge funds.

CRL has been the topic of a number of recent research reports. boosted their target price on Charles River Laboratories International from $350.00 to $355.00 and gave the company a “neutral” rating in a report on Friday, May 28th. Wells Fargo & Company lifted their price target on Charles River Laboratories International from $375.00 to $470.00 and gave the company an “overweight” rating in a research note on Thursday, August 5th. Citigroup lifted their price target on Charles River Laboratories International from $350.00 to $355.00 and gave the company a “neutral” rating in a research note on Friday, May 28th. JPMorgan Chase & Co. lifted their price target on Charles River Laboratories International from $375.00 to $390.00 and gave the company an “overweight” rating in a research note on Friday, May 28th. Finally, Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating and set a $458.00 price target on the stock. in a research note on Wednesday, September 15th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $400.79.

In other news, VP Birgit Girshick sold 81 shares of the company’s stock in a transaction on Monday, September 13th. The stock was sold at an average price of $442.19, for a total value of $35,817.39. Following the sale, the vice president now directly owns 30,025 shares in the company, valued at $13,276,754.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David Ross Smith sold 1,750 shares of the company’s stock in a transaction on Monday, August 9th. The shares were sold at an average price of $407.40, for a total value of $712,950.00. The disclosure for this sale can be found here. Insiders sold 40,900 shares of company stock worth $16,673,320 over the last 90 days. Company insiders own 1.20% of the company’s stock.

CRL opened at $433.05 on Tuesday. The business’s fifty day moving average is $417.76 and its two-hundred day moving average is $359.03. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.15 and a current ratio of 1.36. The company has a market cap of $21.82 billion, a price-to-earnings ratio of 55.81, a PEG ratio of 3.07 and a beta of 1.14. Charles River Laboratories International, Inc. has a one year low of $205.97 and a one year high of $450.84.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Tuesday, August 3rd. The medical research company reported $2.61 EPS for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.23. Charles River Laboratories International had a return on equity of 23.59% and a net margin of 12.10%. The company had revenue of $914.61 million for the quarter, compared to the consensus estimate of $880.72 million. During the same period in the previous year, the business earned $1.58 earnings per share. Charles River Laboratories International’s quarterly revenue was up 34.0% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post 10.25 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

See Also: Is it better to buy a fund with a higher or lower NAV?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.